Core Viewpoint - First Pharmaceutical (600833.SH) is undergoing a property acquisition process in Shanghai's Huangpu District, which involves the compensation for eight properties used primarily for storage and some rental operations [1][2]. Group 1: Property Acquisition Details - The properties involved in the acquisition are located at 360 Lane 12, Beijing East Road, Huangpu District, Shanghai, and include eight adjacent units [1]. - The properties are leased by First Pharmaceutical's wholly-owned subsidiary, First Pharmaceutical Chain Store Co., Ltd. (referred to as "Yi Yi Chain") [1]. - The acquisition is part of the Huangpu District's urban redevelopment plan, with the compensation agreement being reached after multiple negotiations [1]. Group 2: Compensation Agreement - According to the compensation agreement, Yi Yi Chain will receive a total compensation of 32.776 million yuan for the eight properties [2]. - The payment is scheduled to be made within 90 days after the agreement takes effect, and after the relocation and signing of the settlement document [2].

Core Viewpoint - The company is actively expanding its presence in the Shanghai area with a focus on community health services through its network of pharmacies [1] Group 1: Company Operations - The company currently operates 208 stores in the Shanghai region [1] - The company aims to cover a 15-minute convenience circle for local residents [1] - All store locations can be accessed via Gaode Map, enhancing visibility and accessibility for community residents [1]

证券代码：600833 证券简称：第一医药 公告编号：临 2025-046 上海第一医药股份有限公司 关于 2025 年半年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海第一医药股份有限公司（以下简称"公司"）2025 年半年度业绩说明 会于 2025 年 9 月 26 日（星期五）下午 15:00-16:00 通过上海证券交易所上证路 演中心（网址：http://roadshow.sseinfo.com/）以网络互动的方式召开。现将 本次说明会召开情况公告如下： 一、本次说明会召开情况 2025 年 9 月 19 日，公司在上海证券交易所网站（www.sse.com.cn）披露了 《关于召开 2025 年半年度业绩说明会的公告》（公告编号：临 2025-045）。 公司党委书记、董事长张海波先生，党委副书记、副董事长、总经理姚军先 生，独立董事汪丰先生、唐松莲女士、陈少雄先生以及董事会秘书、财务总监孙 峥先生出席了本次说明会，就公司 2025 年半年度的经营成果及财务指标等情况 与投资者进行 ...

Market Overview - On September 24, the pharmaceutical commercial sector rose by 0.12% compared to the previous trading day, with Yifeng Pharmacy leading the gains [1] - The Shanghai Composite Index closed at 3853.64, up 0.83%, while the Shenzhen Component Index closed at 13356.14, up 1.8% [1] Stock Performance - Yifeng Pharmacy (603939) closed at 25.29, with a gain of 3.06% and a trading volume of 74,600 shares, amounting to a transaction value of 189 million [1] - Other notable performers included: - Yao Yigou (300937) at 27.01, up 2.70% [1] - First Pharmaceutical (600833) at 14.12, up 2.54% [1] - Run Da Medical (603108) at 16.12, up 2.15% [1] - Liu Pharmaceutical Group (603368) at 19.65, up 1.71% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 69.46 million from institutional investors, while retail investors saw a net inflow of 46.06 million [2] - The capital flow for individual stocks showed: - Shanghai Pharmaceutical (601607) had a net inflow of 29.57 million from institutional investors [3] - Liu Pharmaceutical Group (603368) saw a net inflow of 21.71 million from institutional investors [3] - Yifeng Pharmacy (603939) had a net inflow of 4.22 million from institutional investors [3]

Core Insights - The 19th China Time-Honored Brand Expo is being held in Shanghai from September 19 to 21, showcasing over 200 time-honored brands and 170 new products, with a theme of "Inheritance and Innovation" [1][9] - The expo highlights the integration of traditional craftsmanship with modern consumer demands, leading to a surge in national trend consumption [1][8] Group 1: Product Innovation - The food and beverage sector is leveraging cross-industry collaborations, such as the "Nong Hao Shanghai" gift box that combines traditional pastries with modern design elements [2][3] - 72% of new food products feature low-sugar and zero-additive recipes, while 65% are packaged in smaller, portable formats to appeal to younger consumers [3][8] - New product offerings include innovative items like the "搭饭" series from Shanghai Meilin, which provides convenient meal options for fast-paced lifestyles [6] Group 2: Technological Advancements - The expo showcases technological innovations, such as the Ice Spring Cotton T-shirt that offers a cooling effect exceeding industry standards by 1.6 times [4] - The eyewear industry is also innovating with a collaboration that integrates art and technology, featuring a seven-in-one automatic eye examination device [4] Group 3: Cultural Integration - The event emphasizes the cultural significance of products, with brands like Dragon and Phoenix embracing modern aesthetics while preserving traditional techniques [5][8] - The integration of traditional brands with contemporary culture is evident, as seen in the collaboration between Wu Liangcai glasses and Dunhuang Museum [8] Group 4: Market Trends - The expo reflects a shift in consumer preferences, with 78% of families seeking comprehensive health solutions, leading to the creation of all-age health spaces [7] - The event also features immersive experiences that blend nostalgia with modern technology, attracting significant consumer engagement [7][8]

投资者可于 2025 年 9 月 19 日（星期五）至 9 月 25 日（星期四）16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 shcred@online.sh.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 证券代码：600833 证券简称：第一医药 公告编号：临 2025-045 上海第一医药股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 9 月 26 日（星期五）下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 上海第一医药股份有限公司（以下简称"公司"）已于 2025 年 8 月 20 日发 布公司 2025 年半年度报告，为便于广大投资者 ...

Market Overview - The pharmaceutical commercial sector increased by 0.19% on September 16, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Top Gainers - Saily Medical (603716) closed at 31.80, up 5.75% with a trading volume of 461,500 shares and a transaction value of 1.457 billion [1] - First Pharmaceutical (600833) closed at 14.33, up 3.47% with a trading volume of 159,400 shares and a transaction value of 229 million [1] - Ruikang Pharmaceutical (002589) closed at 3.05, up 2.35% with a trading volume of 564,800 shares and a transaction value of 170 million [1] Other Notable Stocks - Haiwang Biological (000078) closed at 2.72, up 1.87% with a trading volume of 472,600 shares and a transaction value of 128 million [1] - Yiyigou (300937) closed at 28.06, up 1.41% with a trading volume of 13,100 shares and a transaction value of 36.54 million [1] Market Capital Flow - The pharmaceutical commercial sector saw a net inflow of 1.0663 million from institutional investors, while retail investors had a net inflow of 3.2772 million [2] - However, speculative funds experienced a net outflow of 33.8383 million [2] Individual Stock Capital Flow - Saily Medical had a net inflow of 99.8444 million from institutional investors, while it faced a net outflow of 39.1679 million from speculative funds [3] - First Pharmaceutical saw a net inflow of 21.4721 million from institutional investors, but a net outflow of 2.02355 million from retail investors [3] - Ruikang Pharmaceutical had a net inflow of 8.2730 million from institutional investors, with a slight net outflow from speculative funds [3]

Group 1 - The core viewpoint of the news is that Shanghai First Pharmaceutical Co., Ltd. experienced a stock price increase of 5.2%, reaching 14.57 yuan per share, with a total market capitalization of 3.25 billion yuan [1] - The company is primarily engaged in pharmaceutical retail and wholesale, established in 1992 and listed in 1994 [1] - The trading volume for the stock was 130 million yuan, with a turnover rate of 4.07% [1] Group 2 - According to data, GF Fund's Guangfa Innovation Upgrade Mixed Fund (002939) entered the top ten circulating shareholders of First Pharmaceutical, holding 2.7467 million shares, which is 1.23% of the circulating shares [2] - The fund has achieved a year-to-date return of 35.77% and a one-year return of 77.71%, ranking 1923 out of 8174 and 1157 out of 7982 in its category, respectively [2] - Since its inception, the fund has generated a return of 155.89% [2] Group 3 - The fund manager Liu Gesong has a tenure of 12 years and 28 days, with a total fund asset size of 29.462 billion yuan and a best return of 145.13% during his tenure [3] - Co-manager Wu Yuanyi has a tenure of 4 years and 353 days, managing assets of 20.478 billion yuan, with a best return of 107.14% [3]

Market Overview - On September 12, the pharmaceutical commercial sector declined by 0.51%, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) leading with a 10.01% increase, closing at 31.31 [1] - Other notable performers included Haiwang Biological (000078) with a 2.69% increase and Runda Medical (603108) with a 1.30% increase [1] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 295 million yuan from institutional investors, while retail investors experienced a net outflow of 113 million yuan [2] - Major stocks like Seer Medical had a significant net inflow of 5.15 billion yuan from institutional investors, while retail investors showed a net outflow of 2.61 billion yuan [2]

Meeting Overview - The shareholders' meeting of Shanghai First Pharmaceutical Co., Ltd. was held on September 4, 2025, at the company's office in Shanghai [1] - The meeting was presided over by the vice chairman, Mr. Yao Jun, due to the absence of the chairman, Mr. Zhang Haibo [1] - The voting method combined on-site and online voting, complying with relevant laws and regulations [1] Voting Results - Two ordinary resolutions were presented and approved by the shareholders present at the meeting [2] - For the first resolution regarding the appointment of the auditing firm, 112,412,276 votes (99.7660%) were in favor, with 244,350 votes (0.2169%) against, and 19,300 votes (0.0171%) abstaining [2] - For the second resolution concerning the reappointment of the internal control auditing firm, 112,411,876 votes (99.7657%) were in favor, with 244,750 votes (0.2172%) against, and 19,300 votes (0.0171%) abstaining [2] Legal Compliance - The meeting's procedures, participant qualifications, proposals, and voting processes were confirmed to comply with the Company Law, Securities Law, and other relevant regulations [4] - The resolutions passed during the meeting were deemed legal and valid [4]